2 completed, 2 terminated, 2 withdrawn. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 2, Terminated 2, Withdrawn 2 |
Follow odanacatib: new trials by email Literature Review of odanacatib trials Research Report on odanacatib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) odanacatib, placebo to odanacatib - Osteoporosis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 135 | 2013-03-14 | 2019-09-04 |
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) Odanacatib, Alendronate, Placebo (odanacatib) - Osteoporosis, Postmenopausal Osteoporosis | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2012-05-01 | 2015-08-27 | |
| A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053) Odanacatib, Placebo for Odanacatib, Vitamin D3 - Osteoporosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 294 | 2010-06-09 | 2018-08-28 |
| Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) Odanacatib, Placebo, Vitamin D3 - Osteoporosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 214 | 2008-10-02 | 2018-08-27 |
| A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) odanacatib, placebo (unspecified) - Prostate Cancer | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2008-09-01 | 2016-08-12 | |
| A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) Odanacatib, Placebo for Odanacatib, Vitamin D3 - Postmenopausal Osteoporosis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 16071 | 2007-09-13 | 2024-06-11 |
Osteoporosis (4) · Osteoporosis, Postmenopausal (2) · Prostatic Neoplasms (1)
PMID 23337728, PMID 24898537, PMID 31676222, PMID 32119749, PMID 33200257, PMID 33724542, PMID 35711006